Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis.
Pietro BearziLuca NavariniDamiano CurradoAnnalisa MarinoMarco MinerbaChiara SalvoliniAntonio PerroneLeonardo FrascàVasiliki LiakouliMarta VomeroOnorina BerardicurtiRoberto GiacomelliPublished in: Clinical and experimental rheumatology (2024)
Bosentan significantly decreases sPAP, a relevant prognostic marker, especially in overt SSc-PAH. However, bosentan did not decrease sPAP when started for DU/mixed indication nor for follow-up>1 year. The burden of publication bias was significant. Therefore, further studies are required to assess bosentan's haemodynamic effect in high-risk patients for SSc-PAH.
Keyphrases
- pulmonary hypertension
- pulmonary arterial hypertension
- systemic sclerosis
- pulmonary artery
- interstitial lung disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- left ventricular
- blood pressure
- heart failure
- peritoneal dialysis
- prognostic factors
- polycyclic aromatic hydrocarbons
- mitral valve
- rheumatoid arthritis
- coronary artery
- patient reported